Syneos Health (NASDAQ:SYNH) will post its quarterly earnings results before the market opens on Tuesday, November 6th. Analysts expect Syneos Health to post earnings of $0.60 per share for the quarter. Syneos Health has set its FY18 guidance at $2.84-3.10 EPS.Parties that wish to register for the company’s conference call can do so using this link.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings data on Thursday, August 2nd. The company reported $0.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.61 by $0.01. Syneos Health had a negative net margin of 4.32% and a positive return on equity of 7.80%. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.09 billion. The business’s revenue was up 315.5% on a year-over-year basis. On average, analysts expect Syneos Health to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
SYNH opened at $44.67 on Tuesday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.04 and a current ratio of 1.04. Syneos Health has a 1-year low of $31.10 and a 1-year high of $59.45. The firm has a market cap of $4.62 billion, a price-to-earnings ratio of 23.03, a price-to-earnings-growth ratio of 1.06 and a beta of 0.81.
In related news, major shareholder H. Lee Equity Fund Vi Thomas sold 6,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were sold at an average price of $49.73, for a total value of $298,380,000.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.57% of the company’s stock.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Recommended Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.